Gilead Invests Up to $2 Billion in Galapagos' Anti-inflammatory Drug

Gilead Invests Up to $2 Billion in Galapagos' Anti-inflammatory Drug

Foster City, Calif.-based Gilead Sciences, Inc. (GILD) and Mechelen, Belgium-based Galapagos NV (GLPG) announced today that they had inked a deal to develop and commercialize filgotinib for inflammatory diseases. Gilead will pay Galapagos an upfront …

(Visited 2 times, 1 visits today)
7
Like
Save

Comments

Comments are disabled for this post.